These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12195270)

  • 1. Characterizing and developing strategies for the treatment of community-acquired pneumonia at a community hospital.
    Fok MC; Kanji Z; Mainra R; Boldt M
    Can Respir J; 2002; 9(4):247-52. PubMed ID: 12195270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia.
    Lee RW; Lindstrom ST
    Respirology; 2007 Jan; 12(1):111-6. PubMed ID: 17207035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
    Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
    Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
    Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved management of community-acquired pneumonia in the emergency department.
    Julián-Jiménez A; Palomo de los Reyes MJ; Parejo Miguez R; Laín-Terés N; Cuena-Boy R; Lozano-Ancín A
    Arch Bronconeumol; 2013 Jun; 49(6):230-40. PubMed ID: 23477946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic therapy for inpatients with community-acquired pneumonia in a developing country.
    Trinh HT; Hoang PH; Cardona-Morrell M; Nguyen HT; Vu DH; Dong PT; Cao TT; Nguyen ST; Pham VT; Moss L; Dinh K; Dartnell J; Nguyen HT
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):129-36. PubMed ID: 24648269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
    Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
    Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can an antimicrobial stewardship program reduce length of stay of immune-competent adult patients admitted to hospital with diagnosis of community-acquired pneumonia? Study protocol for pragmatic controlled non-randomized clinical study.
    DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
    Trials; 2015 Aug; 16():355. PubMed ID: 26272324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One drug or two? Step-down therapy after i.v. antibiotics for community-acquired pneumonia.
    Harrington Z; Barnes DJ
    Intern Med J; 2007 Nov; 37(11):767-71. PubMed ID: 17908087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
    Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
    Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010-2018.
    Kimura T; Ito M; Onozawa S
    J Infect Chemother; 2020 Jul; 26(7):706-714. PubMed ID: 32284180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
    Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
    BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia.
    Lee RW; Lindstrom ST
    Respirology; 2007 Sep; 12(5):754-8. PubMed ID: 17875067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
    Rhedin S; Galanis I; Granath F; Ternhag A; Hedlund J; Spindler C; Naucler P
    Clin Microbiol Infect; 2017 Apr; 23(4):247-252. PubMed ID: 28017793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-acquired pneumonia team decreases length of stay in hospitalized, low-risk patients with pneumonia.
    Marcos PJ; Restrepo MI; Sanjuàn P; Ferreira-Gonzalez L; Verea-Hernando H
    Hosp Pract (1995); 2013 Aug; 41(3):7-14. PubMed ID: 23948616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.
    Stahl JE; Barza M; DesJardin J; Martin R; Eckman MH
    Arch Intern Med; 1999 Nov; 159(21):2576-80. PubMed ID: 10573047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.